Ignite Creation Date:
2024-05-05 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 9:53 AM
Study NCT ID:
NCT00736593
Status:
COMPLETED
Last Update Posted:
2009-04-27
First Post:
2008-08-14
Brief Title:
A Study Evaluating Nexagon in the Treatment of Skin Wounds
Sponsor:
OcuNexus Therapeutics Inc
Organization:
OcuNexus Therapeutics Inc
Study Overview
Official Title:
A Phase 1 Randomized Prospective Within-Subject Double-Blind Vehicle-Controlled Dose-Escalation Study to Evaluate the Safety Tolerability and Clinical Effect of Nexagon in Full-Thickness Punch Wounds
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Nexagon is a novel compound that promotes wound healing by temporarily disrupting cellular communication at the wound site thereby promoting accelerated healing reducing inflammation and pain This randomized double-blind study will assess the safety tolerability and clinical effect of Nexagon when applied to skin wounds created by punch biopsy in healthy volunteers 43 healthy fair-skinned males and females between ages 18-40 will be enrolled Subjects will be reviewed again at 3 months and 9 months for follow-up safety assessments and wound appearance evaluation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None